Highlights d Wild-type p53 correlates with reduced expression of genes in the mevalonate pathway d p53 null liver tumorigenesis in mice depends on activation of the mevalonate pathway d p53-mediated ABCA1 expression inhibits maturation of SREBP-2 d Abca1 functions as a tumor suppressor in mouse liver
SUMMARY
There are still gaps in our understanding of the complex processes by which p53 suppresses tumorigenesis. Here we describe a novel role for p53 in suppressing the mevalonate pathway, which is responsible for biosynthesis of cholesterol and nonsterol isoprenoids. p53 blocks activation of SREBP-2, the master transcriptional regulator of this pathway, by transcriptionally inducing the ABCA1 cholesterol transporter gene. A mouse model of liver cancer reveals that downregulation of mevalonate pathway gene expression by p53 occurs in premalignant hepatocytes, when p53 is needed to actively suppress tumorigenesis. Furthermore, pharmacological or RNAi inhibition of the mevalonate pathway restricts the development of murine hepatocellular carcinomas driven by p53 loss. Like p53 loss, ablation of ABCA1 promotes murine liver tumorigenesis and is associated with increased SREBP-2 maturation. Our findings demonstrate that repression of the mevalonate pathway is a crucial component of p53-mediated liver tumor suppression and outline the mechanism by which this occurs.
INTRODUCTION
p53, a major tumor suppressor, has multiple effector functions, such as cell-cycle arrest, cell death, senescence, and DNA repair (Vousden and Prives, 2009 ). Together with the aforesaid canonical tumor-suppressive functions, p53 not only responds to metabolic challenges from nutrient depletion (Feng et al., 2005; Jones et al., 2005; Maddocks et al., 2013) but also regulates numerous metabolic pathways to restrict cell growth (Vousden and Ryan, 2009 ). The roles of p53 in various aspects of cellular metabolism and their contribution to its tumor-suppressive functions are still under active investigation.
We previously discovered that cancer-derived missense mutations in p53 are correlated with increased expression of mevalonate pathway genes, which contributes to the malignant morphology of breast cancer cells (Freed-Pastor et al., 2012) . The mevalonate pathway is the route by which cells produce sterols such as cholesterol and non-sterol isoprenoids. Cholesterol is an important component of cellular membranes and serves as a precursor for steroid hormones and vitamin D. Isoprenoids are used for synthesis of important biomolecules, such as dolichol, heme A, ubiquinone, and coenzyme Q, as well as the hydrophobic chains that anchor proteins such as Ras and Rho to the cell membrane for signal transduction. Accordingly, this pathway has been implicated in multiple aspects of tumorigenesis (reviewed in Mullen et al. [2016] ).
The rate-limiting step of the mevalonate pathway is controlled by 3-hydroxy-3-methyl-glutaryl (HMG)-coenzyme A (CoA) reductase (HMGCR), an enzyme that converts HMG-CoA to mevalonate and is the target of cholesterol-reducing statins (Larsson, 1996) . Interestingly, statins have been associated with reduced mortality in multiple cancer types, including prostate, kidney, colorectal, breast, and lung cancer (Alfaqih et al., 2017; Cardwell et al., 2015; Gray et al., 2016; Huang et al., 2016; Manthravadi , 2015) . Because some studies have not reported beneficial effects of statins (Carrat, 2014; Dale et al., 2006) , further clarification of the factors involved in mediating their potential anti-tumor effects are needed. The master regulator of mevalonate pathway genes, the transcription factor SREBP-2, is synthesized as an inactive precursor embedded in the endoplasmic reticulum (ER) (Brown and Goldstein, 1997; Horton et al., 2002) . Upon cholesterol depletion in the ER, this precursor is transported to the Golgi and cleaved to its active mature form, which then translocates to the nucleus to activate transcription of mevalonate pathway genes by binding to sterol regulatory elements (SREs) in their promoters. SREBP-2 maturation can be triggered abruptly when ER cholesterol levels fall below a threshold (Radhakrishnan et al., 2008) . Trafficking of cholesterol is mediated by proteins such as ATP-binding cassette (ABC) transporters (Tarling et al., 2013) . In particular, ABCA1, ABCG1, ABCG4, ABCG5, and ABCG8 are known to transport cholesterol across membranes, but their implication in cancer has not been extensively investigated.
Because we previously implicated mutant p53 in upregulating the mevalonate pathway and because, in some cases, there exists a reciprocal relationship between the effect of wild-type (WT) and mutant p53 on gene expression and outcomes (Freed-Pastor and Prives, 2012) , we hypothesized that WT p53 might actively repress mevalonate pathway genes. Testing this idea revealed a heretofore unexplored pathway by which p53 can suppress tumorigenesis.
RESULTS p53 Represses Mevalonate Pathway Gene Expression
To investigate whether p53 might downregulate the mevalonate pathway, we first activated endogenous WT p53 in different cells. After treatment with Nutlin-3, a p53 activator, the expression of numerous genes in the mevalonate pathway was markedly repressed in SK-HEP-1 cells, mouse embryonic fibroblasts (MEFs), and HCT116 cells ( Figures 1A-1C and S1A). Similar results were observed in Hep3B-4Bv cells that stably express a temperature-sensitive mutant p53 (Friedman et al., 1997) , where re-activation of WT p53 at the permissive temperature led to downregulation of mevalonate pathway genes, whereas expression of p21, a canonical p53 target, was increased ( Figure S1B ).
Additionally, in murine liver, tumors harboring a tetracyclineregulated p53 short hairpin RNA (shRNA) (Xue et al., 2007; Figure S1C) , p53 reactivation led to a marked downregulation of genes involved in steroid and cholesterol biosynthesis , which included 15 mevalonate pathway genes (Figure S1D) . p53 restoration in cultured liver progenitor cells also led to repressed expression of mevalonate pathway genes (Figure 1E) , demonstrating that p53-mediated suppression of the mevalonate pathway is a cell-intrinsic mechanism.
Further, examination of the Cancer Cell Line Encyclopedia (CCLE) (Barretina et al., 2012) revealed that p53 null and p53 mutant cancer cells display higher levels of mevalonate pathway gene expression compared with cancer cell lines with WT p53 (Figures 1F and S1E) .
Collectively, these data indicate an inverse correlation between WT p53 and mevalonate pathway gene expression across multiple cell lines and tissue types.
p53 Inhibits SREBP-2 Maturation under Low-Sterol Conditions We examined whether differences in p53 status result in differential activation of the pathway under sterol-depleted conditions using the isogenic pair of HCT116 WT (p53 +/+ ) and HCT116 p53 À/À cells. When cultured in sterol-depleted medium, p53 À/À cells showed more robust activation of mevalonate pathway genes than WT cells (Figure 2A ). In a more physiological setting, HCT116 cells grown on a Matrigel matrix form spheroid-like structures, which is akin to the in vivo tumor microenvironment, where nutrients such as exogenous sterols are depleted. After 9 days, both WT and p53 À/À spheroids had increased in size comparably, suggesting that both isogenic lines were growing at a similar rate ( Figure S2A ). However, activation of HMGCR mRNA expression (likely resulting from sterol depletion in this setting) was significantly greater in p53 À/À spheroids (5.1-fold) than in WT spheroids (2.8-fold) ( Figure 2B ).
Consistent with the expression analysis of mevalonate pathway genes, quantitative chromatin immunoprecipitation (ChIP) analysis showed increased binding of SREBP-2 to the promoters of mevalonate pathway genes in p53 À/À cells compared with WT cells ( Figure 2C ). Note that SREBF-2 mRNA expression (encoding SREBP-2) was not affected by p53 loss (Figures 2A and 2B ), suggesting that post-transcriptional changes might be responsible for increased SREBP-2 binding to those promoters in p53 À/À cells. Indeed, immunoblot analysis revealed that p53 loss in HCT116 cells led to increased levels of the mature form of SREBP-2 under sterol-depleted conditions ( Figures 2D-2F ). Conversely, p53 activation led to reduced levels of the mature form of SREBP-2 in SK-HEP-1 and Hep3B-4Bv cells ( Figures 2G and 2H ). The level of mature SREBP-2 in HCT116 p53 À/À cells was strongly decreased by and p53 À/À ) (B), and HCT116 WT (p53 +/+ ) and p53 À/À cells (C) were treated with either DMSO or Nutlin-3 for 24 hr, and expression of the mevalonate pathway genes was assessed by qRT-PCR. Error bars represent SD of the mean (n = 3, *p < 0.01). (D) Gene ontology analysis of gene sets that were significantly downregulated upon p53 restoration in murine liver carcinomas (left). Gene set enrichment analysis (GSEA) was used to evaluate changes in the gene signature of cholesterol synthesis upon p53 restoration (right). (E) Mouse liver progenitor cells transduced in vitro with H-rasV12 linked to the tetracycline transactivator protein tTA (tet off) and tetracycline responsive p53 shRNA were cultured in the presence of doxycycline to restore p53 expression and harvested on days 0, 4, and 8. Expression of the mevalonate pathway genes was assessed by qRT-PCR (n = 3). Error bars represent SDs of the means. (F) A condensed mevalonate pathway gene expression signature value was calculated for each line in the CCLE. The mevalonate pathway signature values were compared among all p53 WT (n = 333), p53 null (n = 151), and p53 missense (n = 373) lines (mean ± SEM). p = 0.0059 as determined by an unpaired two-tailed t test. (legend on next page) addition of 25-hydroxycholesterol, which holds SREBP-2 in the ER and blocks its maturation (Adams et al., 2004 ; Figure 2D ). Additionally, the level of mature SREBP-2 in p53 À/À cells was markedly greater than in WT cells in the presence of N-Acetyl-Leucyl-Leucyl-norleucinal (ALLN), a protease inhibitor that blocks SREBP degradation (Wang et al., 1994 ; Figure S2B ). Sterol depletion led to neither an increase in p53 protein levels ( Figure 2D ) nor significant p53 binding to the promoters of select mevalonate pathway genes ( Figure S2C ), suggesting that p53-mediated repression of these genes is indirect.
The Mevalonate Pathway Is Activated in p53 null Cancer Cells and Allows Cell-Cycle Progression under Low-Sterol Conditions A mass spectrometry metabolomics analysis revealed significant increases in the levels of several metabolic intermediates, including phosphomevalonate and diphosphomevalonate, in the p53 null cells compared with the parental (WT p53) cells ( Figure 3A ). However, certain other metabolites that could be measured were not significantly increased ( Figure S3A ), indicating that factors distinct from p53-mediated control of mevalonate pathway gene expression also influence the levels of the pathway's intermediates. Although limited by the steady-state nature of the analysis, a decrease in mevalonate and an increase in the phosphomevalonate/mevalonate ratio were observed, implying that p53 control of mevalonate pathway gene expression can produce detectable changes in metabolic flux. Future studies will be necessary to assess how the rewiring of the pathway occurs and which intermediates and byproducts of the pathway actually contribute to the oncogenic physiology of p53 null cancer cells. We then assessed the cell-cycle distribution upon sterol starvation. Compared with WT cells, p53 À/À cells displayed increased progression into S phase after sterol starvation, which was most pronounced at 24 and 32 hr ( Figure 3B ) and was accompanied by a marked increase in the levels of mature SREBP-2 ( Figure 3C ). G1 arrest was reinforced by treatment with either simvastatin or GGTI-2133, inhibitors of HMGCR and geranylgeranyltransferase, respectively. These responses were rescued by supplementation of mevalonate pathway metabolites such as mevalonic acid 5-phosphate (MVAP) and geranylgeranyl pyrophosphate (GGPP) ( Figure 3D ). This indicates that activation of the mevalonate pathway provides metabolites necessary for sustaining cell-cycle progression, which include GGPP. In line with this, knockdown of HMGCR resulted in a more robust decrease in S phase in p53 null cells compared with the parental (WT p53) cells ( Figure 3E ). Such regulation likely becomes particularly important under conditions of nutrient depletion that accompany tumor formation.
It is unlikely that changes in SREBP-2 maturation were simply results of changes in growth or the cell cycle, resulting from differential p53 status. First, although similar amounts of cells in S phase were detected at 24 hr in WT (p53 +/+ ) cells and at 32 hr in p53 À/À cells ( Figure 3B ), at those time points, there was markedly more mature SREBP-2 in p53 À/À cells than in WT cells ( Figure 3C ). Second, the isogenic pair of SK-HEP-1 parental (WT p53) and p53 null cells exhibited similar proliferation rates, as determined by cell counting ( Figure S3B ). Third, when the cell cycle was arrested by the CDK inhibitors roscovitine and palbociclib ( Figure S4I ), SREBP-2 maturation was still elevated in p53 null cells ( Figure S3C ). These results indicate that p53 inhibition of SREBP-2 maturation can be independent of proliferation rate or cell-cycle stage.
ABCA1 Is a p53 Target Gene that Inhibits SREBP-2 Maturation
The cholesterol transport protein ABCA1 was recently reported to mediate retrograde sterol movement from the plasma membrane to the ER, repressing SREBP-2 maturation in MEFs (Yamauchi et al., 2015) . In line with this, ABCA1 knockdown increased the levels of mature SREBP-2 in SK-HEP-1 cells with and without p53 (Figures 4A and 4B) . We therefore considered the possibility that activation of ABCA1 by p53 might explain its role in decreasing SREBP-2 maturation. Indeed, Nutlin-3 treatment increased ABCA1 mRNA and protein expression in SK-HEP-1 and HCT116 cells (Figures 4C and 4D) , along with a concomitant increase in p53 protein associated with two ABCA1 promoter regions (transcription start site [TSS] +110 bp and TSS +1,690 bp) spanning putative p53 response elements (Figures 4E and S4A) . Further, p53 induction of ABCA1 mRNA and protein expression required its transactivation domain ( Figure S4B ), whereas p53 depletion using RNAi or CRISPR/ Cas9 reduced ABCA1 mRNA expression ( Figure 4F ). Consistent with results from human cells, p53 restoration induced Abca1 Figure 2 . p53 Inhibits SREBP-2 Maturation under Low-Sterol Conditions (A) HCT116 cells were cultured for 24 hr in medium plus fetal bovine serum (FBS; gray bars), delipidated FBS (DL-FBS; black bars), or delipidated FBS plus 25-hydroxycholesterol (DL-FBS+25-HC; white bars). Expression of HMGCR, HMGCS1, and SREBF-2 was assessed by qRT-PCR (n = 3; *p < 0.01; n.s., not significant). Error bars represent SD of the means. (B) HCT116 cells were grown on Matrigel to form spheroids. The spheroids were harvested on day 3 (gray bars) and day 9 (black bars). mRNA expression of HMGCR and SREBF-2 genes was assessed by qRT-PCR (n = 3, *p < 0.01). Error bars represent SDs of the means. (C) HCT116 cells were cultured in sterol-depleted medium for 24 hr and subjected to ChIP analysis (n = 2, *p < 0.03). HMGCR (TSS À1,100) is a negative control region for SREBP-2 binding. HMGCR (TSS À150), HMGCS1 (TSS À115), and FDPS (TSS À260) correspond to known sterol regulatory elements (SREs) in the respective promoter genes. Error bars represent SDs of the means. (D-H) Cells were grown under the indicated conditions prior to lysis and immunoblotting analysis to detect full-length precursor (P) and mature (M) SREBP-2 polypeptides, p53, or actin. (D) HCT116 cells were cultured for 24 hr as in (A) in FBS (1), DL-FBS (2), or DL-FBS+25-HC (3). (E) HCT116 cells were transfected with control luciferase (Luc) siRNA or two p53 siRNAs and sterol-starved for 24 hr. (F) HCT116 spheroids on day 9 as in (B) were subjected to immunoblot analysis. (G) SK-HEP-1 cells were cultured in sterol-depleted medium along with either DMSO or Nutlin-3 for 24 hr. (H) Hep3B-4Bv cells expressing temperature-sensitive mutant p53 and the parental Hep3B cells were cultured for 72 hr at either 37 C or 32 C. mRNA expression in murine liver progenitor cells ( Figure S4D ). Finally, analysis of a human hepatocellular carcinoma (HCC) database (The Cancer Genome Atlas [TCGA]-liver hepatocellular carcinoma [LIHC]) showed that ABCA1 expression levels are lower in human HCC harboring p53 missense mutations than those with WT p53 ( Figure 4G ), as are two other well validated p53 targets, CDKN1A and BBC3 ( Figure S4E ). In response to sterol starvation, the protein levels of mature SREBP-2 increased rapidly in p53 null cells, where ABCA1 expression was significantly reduced compared with the parental (WT p53) cells ( Figure 4H ). Upon extended sterol starvation, we observed that ABCA1 protein levels were gradually decreased, as reported previously (Hsieh et al., 2014) , and the levels of mature SREBP-2 were concomitantly increased, indicating a mechanistic link between ABCA1 and SREBP-2 maturation.
Importantly, ABCA1 depletion by small interfering RNA (siRNA) led to increased SREBP-2 maturation even in a p53 null setting. This reinforces the effect of ABCA1 on SREBP-2 maturation and provides an indication of how p53 modulates the mevalonate pathway through ABCA1 expression. This was confirmed by results where treatment of p53 null cells with agonists of RXR ( Figure 4I ) and LXR ( Figure S4C ) activated ABCA1 expression dramatically, with concomitant reduced levels of mature SREBP-2. Decreased mature SREBP-2 was not seen in ABCA1 siRNA-transfected cells, demonstrating that ABCA1, among LXR and RXR target genes, is vital for inhibition of SREBP-2 maturation.
That ABCA1 results in repression of genes in the mevalonate pathway in many cancer cell lines was derived from the CCLE dataset, where we found an inverse correlation between ABCA1 and mevalonate pathway gene expression across all cell lines ( Figures S4F and 4J ). This inverse correlation was also observed in the TCGA-colon adenocarcinoma (COAD) human colorectal tumor dataset (Table S5 ).
To assess whether p53's transactivation of ABCA1 was independent of its effects on cell-cycle progression, SK-HEP-1 cells were either asynchronous or highly synchronized by double thymidine block or the CDK4 and CDK6 inhibitor palbociclib. ABCA1 expression was significantly reduced in p53 null cells compared with the p53-expressing parental line . This implies that ABCA1 expression is directly caused by p53 transactivation ( Figure S4B ) rather than an indirect result of p53-mediated cell-cycle changes.
Collectively, these data indicate that p53 can repress the mevalonate pathway through transcriptional upregulation of ABCA1 gene expression, leading to a reduction in SREBP-2 maturation and a corresponding decrease in the transcription of mevalonate pathway genes.
Mevalonate Pathway Gene Expression Is Activated in p53 null Murine Liver Tumorigenesis HCC has recently become the second leading cause of cancerrelated deaths worldwide and represents a tumor type where p53 mutations are common. The mevalonate pathway plays a prominent role in the normal liver, which is responsible for $80% of de novo cholesterol biosynthesis in humans. To assess possible links between p53 and mevalonate pathway gene expression in a relevant tumor protocol, we took advantage of a flexible mouse model of liver carcinoma that allows for somatic engineering of cancer-relevant lesions through hydrodynamic tail vein injection (HTVI) (reviewed in Chen and Calvisi, 2014) . In this approach, recombinant transposon vectors expressing cDNAs or shRNAs (together with a Sleeping Beauty transposase) or CRISPR/Cas9 constructs harboring single guide RNAs (sgRNAs), can be introduced into a subset of hepatocytes, leading to altered gene expression. If these elements target cancer-relevant genes, then the animals eventually develop tumors Manchado et al., 2016; Tschaharganeh et al., 2014) .
We initially validated the links between p53 and the expression of mevalonate pathway genes in these models by co-injecting the MYC oncogene along with CRISPR plasmid DNA expressing Cas9 and sgRNAs targeting either p53 (Dow et al., 2015) or another tumor suppressor, Axin1, that plays an inhibitory role in the Wnt signaling pathway (Polakis, 2000) . This protocol leads to rapid formation of HCC within a few weeks (Figures 5A, 5B, and S5A). HCC cell lines derived from sgp53;MYC and sgAxin1;MYC liver tumors were analyzed by qRT-PCR and immunoblotting. Consistent with the abovementioned findings, expression of the mevalonate pathway genes ( Figure 5C ) and Srebp-2 maturation were elevated in sgp53;MYC lines compared with sgAxin1;MYC lines that retain WT p53 (Figures 5E and 5F) , whereas Abca1 expression was downregulated in sgp53;MYC and p53 R172H/fl ;Alb-Cre;MYC tumors (Figures 5D, 5G, and S5B).
To functionally explore the contribution of the mevalonate pathway during the initial stages of p53-mediated tumor suppression, we looked at changes in gene expression shortly after introduction of the oncogene MYC at a time where p53 is activated for tumor suppression but before the onset of frank tumors that may acquire other events to confound our analysis. Figure 3 . The Mevalonate Pathway Is Activated in p53 null Cancer Cells (A) Metabolomics analyses of mevalonate pathway intermediates isolated from SK-HEP-1 cells with WT p53 or derived p53 null cells was performed via ultra-high pressure liquid chromatography coupled to mass spectrometry (UHPLC-MS) coupled to electrospray ionization (ESI) and atmospheric pressure chemical ionization (APCI) (n = 3, mean ± SEM). (B) HCT116 cells were cultured in sterol-depleted medium and harvested at the indicated time points for flow cytometry analysis. The proportion of cells in S phase was quantitated and plotted (n = 3, *p < 0.01). Error bars represent SDs of the means. (C) HCT116 cells were cultured in sterol-depleted medium and harvested at the indicated time points prior to immunoblot analysis as above. (D) HCT116 cells were cultured for 24 hr in sterol-depleted medium supplemented as indicated: non-treated (NT), simvastatin, mevalonic acid 5-phosphate (MVAP), geranylgeranyl pyrophosphate (GGPP), and GGTI-2133. The proportions of S phase cells were averaged (n = 4, *p < 0.001 for NT versus simvastatin or GGTI-2133, **p < 0.001 for simvastatin versus supplementation of metabolites). Error bars represent SDs of the means. (E) SK-HEP-1 cells were transfected with negative control or HMGCR siRNA, sterol-starved for 24 hr, and harvested for flow cytometry analysis. The proportion of the cells in S phase was quantitated and plotted (n = 2). Error bars represent SDs of the means. Hepatocytes from WT and p53 fl/fl ;Alb-Cre mice were transduced in vivo with an EF1a-MYC-internal ribosome entry site (IRES)-GFP transposon and Sleeping Beauty transposase that were delivered by HTVI. Six days later, transduced livers were digested by collagenase perfusion, and GFP-positive primary hepatocytes were isolated by fluorescence-activated cell sorting (FACS) ( Figure 6A ). RNA sequencing (RNA-seq) analysis was performed on these primary hepatocytes from p53 WT and p53 null livers that acutely overexpressed MYC ( Figure 6B ).
Consistent with our in vitro models, p53 WT but not p53 null hepatocytes responded to enforced MYC expression by inducing Abca1 expression and other established p53 target genes. Importantly, increases in Abca1 were accompanied by a corresponding decrease in many mevalonate pathway genes ( Figure 6B ), and gene set enrichment analysis of the genome-wide dataset further revealed that gene signatures of cholesterol, isoprenoid, and lipid metabolism were significantly downregulated in response to p53 in this setting ( Figure 6C ). To our knowledge, this is the first reported examination of the p53-regulated transcriptome in vivo, where it is actively suppressing tumorigenesis from such an early time, and reinforces the prominence of mevalonate pathway regulation in the p53 tumor-suppressive program.
Derepression of the Mevalonate Pathway Is Necessary for Liver Tumor Development Caused by p53 Loss
To determine whether the increased expression of mevalonate pathway genes was required for p53 loss to cooperate with MYC during tumorigenesis, we co-injected constructs expressing the MYC oncogene and CRISPR/Cas9 and sgRNAs targeting either p53 or Axin1 along with either GFP-linked shRNAs targeting three mevalonate pathway genes (Hmgcr, Sqle, and Lss) that were identified from a previous screen (Huang et al., 2014; Figures S6A and S6B) or control Renilla luciferase (see Figure S6C for the experimental scheme and Figure S6D for histological analysis of tumors). In this system, the linked GFP reporter can be used as a surrogate to identify cells that express the shRNA.
These experiments produced striking results. First, shRNAs targeting each of the mevalonate pathway genes showed a distinct reduction in the fraction of GFP-positive sgp53;MYC tumors that formed compared with tumors produced with control shRNA (shRen) ( Figure 6D ). Second, although shRen tumors were invariably GFP-positive, most sgp53;MYC tumors arising with shSqle.1, shSqle.2, shLss, and shHmgcr lacked GFP, suggesting that they did not take up or express the shRNA ( Figures  6D and S6D ). Third, in sgAxin1-injected mice (which do not require p53 loss to drive tumors), most shRNAs targeting mevalonate pathway enzymes produced a similar fraction of GFP-positive tumors as the control shRNA, and in many instances, the resulting tumors were GFP-positive ( Figures S6F and S6D ). Finally, GFP-positive normal hepatocytes were observed at comparable levels for all shRNAs when mice were transduced in the absence of the oncogene ( Figure S6E ). Thus, suppression of mevalonate pathway enzymes is incompatible with tumor initiation in the absence of p53 but tolerated in tumors driven by Axin1 loss and in normal hepatocytes.
We used pharmacological inhibition of Hmgcr as an orthogonal approach ( Figure S6G ), and to control for variability of tumor burden, both liver weight and tumor number were measured. Here, too, we found that treatment with atorvastatin significantly restricted the formation of sgp53;MYC tumors ( Figure 6E ) but not sgAxin1;MYC tumors ( Figure S6H ). These data provide powerful support for the hypothesis that derepression of the mevalonate pathway is important for the development of liver tumors harboring p53 loss.
Abca1 Suppresses Liver Tumorigenesis
Having identified ABCA1 as a conduit between p53 and control of the mevalonate pathway via SREBP-2 maturation, we examined TCGA datasets of human HCC, colon adenocarcinoma, and breast carcinoma (TCGA-LIHC, COAD, and BRCA, respectively). This revealed that ABCA1 expression was reduced in these tumors compared with normal tissues ( Figure 7A ). Copy number variation analysis also showed that the ABCA1 locus is often lost in human HCC ( Figure 7B ).
These data, suggesting that ABCA1 can have tumor-suppressive activity, were confirmed in experiments where we coinjected constructs expressing the MYC oncogene along with a CRISPR/Cas9 plasmid and sgRNAs that target Abca1 and found that the mice developed tumors more rapidly than controls injected with MYC and sgRNA targeting chromosome 8 (Figure 7F) . Although p53 loss was more potent than Abca1 loss at promoting tumorigenesis, this is not surprising because p53 (A) SK-HEP-1 cells were transfected with negative control siRNA or three ABCA1 siRNAs, sterol-starved for 12 hr, lysed, and subjected to immunoblot analysis. (B) SK-HEP-1 p53 null cells were transfected with negative control siRNA or ABCA1 siRNAs, sterol-starved, and harvested at the indicated time points for immunoblot analysis. (C) SK-HEP-1 cells were treated with either DMSO or Nutlin-3 for 24 hr and then harvested for immunoblot analysis. (D) SK-HEP-1 and HCT116 cells were treated with either DMSO or Nutlin-3 for 24 hr, and ABCA1 mRNA expression levels were assessed by qRT-PCR (n = 3). Error bars represent SDs of the means. (E) SK-HEP-1 cells were treated with Nutlin-3 and subjected to ChIP analysis to examine p53 occupancy at the ABCA1 promoter (n = 2). See Figure S4A for ChIP analysis with HCT116 cells. Error bars represent SDs of the means. (F) SK-HEP-1 cells were transfected with control siRNA or two p53 siRNAs (left). p53 was ablated in SK-HEP-1 (center) and HCT116 (right) cells. ABCA1 mRNA expression levels were assessed by qRT-PCR (n = 3). Error bars represent SDs of the means. (G) Expression of ABCA1 mRNA in human liver tumors with WT p53 (n = 133) and missense mutations (n = 40) was compared (p < 8 3 10 À5 ). (H) SK-HEP-1 parental (WT p53) and p53 null cells were cultured in sterol-depleted medium and harvested at the indicated time points for immunoblot analysis. (I) SK-HEP-1 p53 null cells were transfected with negative control siRNA or ABCA1 siRNAs and sterol-starved for 8 hr in the presence of the RXR agonist LG100268 and then harvested for immunoblot analysis. (J) Analysis of CCLE data comparing the mevalonate pathway gene expression signature in cells with high levels of ABCA1 mRNA versus cells with low levels of ABCA1 mRNA (false discovery rate [FDR]-adjusted p < 2 3 10 À12 ). frequently exerts its tumor-suppressive program through multiple effector pathways (Kastenhuber and Lowe, 2017) . All tested sgAbca1 constructs produced liver tumors ( Figure 7C ) in which loss of Abca1 was confirmed by genomic sequencing and immunofluorescence staining for Abca1 ( Figures S7A and  S7B ). Consistent with our in vitro results and cell line analyses (Figure 4 ), liver tumors produced by Abca1 sgRNAs displayed higher levels of lanosterol synthase ( Figure 7D ), and the mature Srebp-2 protein was elevated in the tumor-derived cells (Figure 7E ). In general, there were no significant differences in apoptosis or proliferation between established tumors of different genotypes ( Figures S7C and S7D ).
Collectively, these data indicate that the p53 effector Abca1 has tumor-suppressive activity in a murine model of liver cancer and reinforce the functional relevance of p53's regulation of the mevalonate pathway in its tumor-suppressive activity.
DISCUSSION
p53 controls many biochemical and biological processes that limit tumor growth, the relative contribution of which can depend on genetic and tissue context (Kastenhuber and Lowe, 2017) .
Here we show that one of these processes can be metabolic control of the mevalonate pathway. Specifically, in our animal modeling experiments, genetic or pharmacological inhibition of this pathway has a preferential effect on development of tumors involving p53 inactivation but not those engineered to leave the p53 gene intact. Interestingly, previous work using a different Myc transgenic model also saw a cancer-preventative effect of statin treatment on HCC, although that study did not assess the status of p53 in the resulting tumors and, instead, attributed the results to an effect of the statin on Myc phosphorylation (Cao et al., 2011) . Whether both mechanisms can contribute to statin sensitivity in HCC remains to be determined. Nonetheless, it is striking that p53-mediated regulation of the mevalonate pathway can be observed in premalignant hepatocytes shortly after MYC overexpression and at a time when p53 must be engaged in the initial stages of tumor suppression. Analysis of more than 800 human cancer cell lines originating from various tissues ( Figure 1F ) leads us to speculate that p53 inhibition of the mevalonate pathway is tumor-suppressive in multiple tumor types.
It is interesting that both missense mutant and WT p53 proteins regulate the mevalonate pathway in opposing ways. Although mutant p53 functions as a coactivator to associate with SREBP-2 at the promoters of some mevalonate pathway genes (Freed-Pastor et al., 2012) , our findings show that WT p53 represses the mevalonate pathway genes through inhibition of SREBP-2 maturation, which results from p53 upregulation of ABCA1 transcription. That both versions of p53 intersect with the master transcriptional regulator SREBP-2 attests to the importance of the mevalonate pathway in cancer.
Our finding that ABCA1 is a bona fide p53 target gene is supported by high-throughput RNA-seq analysis of Nutlin-3-treated HCT116 and MCF-7 cells (Allen et al., 2014; Janky et al., 2014) . Further, our results demonstrating that Abca1 can have tumorsuppressive activity are corroborated by other observations. For example, overexpression of ABCA1 reduces tumor formation of xenografts of human cancer cell lines (Smith and Land, 2012) . Furthermore, ABCA1 expression decreases during prostate cancer progression, and ABCA1 knockdown increases the proliferation rate of prostate cancer cells in culture (Fukuchi et al., 2004) . In ovarian cancer patients, low expression of ABCA1 is associated with a poor prognosis (Chou et al., 2015) . Moreover, LXR agonists that trans-activate ABCA1 and other metabolic genes have anti-proliferative effects in certain cancers (Lin and Gustafsson, 2015) .
Because ABCA1 exports excess cholesterol at the plasma membrane and thereby reduces total cholesterol levels (Lawn et al., 1999; Orsó et al., 2000) , it is somewhat surprising that ABCA1 loss increases SREBP-2 maturation and that it does so independent of p53 status (Figures 4A, 4B , and 7E). Nevertheless, Abca1 loss activates Srebp-2 maturation in MEFs, and Abca1 has been reported to facilitate retrograde sterol transport from the plasma membrane to the ER (Yamauchi et al., 2015) . In fact, an inverse correlation exists between ABCA1 and mevalonate pathway gene expression in both CCLE ( Figure 4J ) and colon adenocarcinoma TCGA (Table S5) datasets. Further, hepatocyte-specific deletion of Abca1 increases the levels of Ldlr mRNA and protein (Ldlr is a direct target of SREBP-2) in mouse liver (Chung et al., 2010) .
We showed that SK-HEP-1 parental cells (WT p53), where ABCA1 proteins are markedly expressed, display gradual increases in SREBP-2 maturation as ABCA1 proteins levels are decreased upon sterol withdrawal ( Figure 4H ). By contrast, in p53 null cells, where ABCA1 is under-expressed, SREBP-2 maturation takes place rapidly. Notably, to induce robust maturation of SREBP-2, ABCA1 loss is not sufficient by itself and has to be accompanied by the duration of sterol starvation. We speculate that WT p53 cells delay the maturation of SREBP-2 by transporting cholesterol into the ER, whereas, in p53 null cells, where ABCA1 is basally under-expressed, cholesterol transport to the ER is impaired, and, therefore, SREBP-2 maturation takes place rapidly.
Although the molecular mechanism by which ABCA1 increases ER cholesterol levels and, therefore, decreases SREBP-2 maturation remains to be determined, our findings demonstrate that activation of ABCA1 transcription is a mechanism by which p53 restricts SREBP-2 maturation. Still, because p53 regulates various aspects of cellular metabolism, it is likely that other metabolic consequences of p53 can contribute to tumor suppression and, moreover, that some may also influence mevalonate pathway expression or activity through Abca1-independent mechanisms (Goldstein et al., 2012) . However, we believe that the under-expression of ABCA1 in p53 null cells is particularly critical for SREBP-2 maturation and expression of the mevalonate pathway gene (Figures 4B, 4G , and 4J; Table  S5 ). Because ABCA1 is such an important gene in the pathway of cholesterol metabolism, it is unlikely that p53 would be its sole regulator. Indeed, as mentioned above, ABCA1 is a wellknown activation target of the nuclear receptor LXR, and agonists of LXR have been shown to have anti-proliferative effects in some cancers (Lin and Gustafsson, 2015) , including HCC (Bellomo et al., 2018; Xiong et al., 2017) . Activation of the mevalonate pathway can contribute to tumorigenesis in various ways (reviewed in Mullen et al., 2016) . Not only mevalonate-derived metabolites, such as cholesterol and the isoprenoids (farnesyl pyrophosphate [FPP] and GGPP), but also downstream signaling pathways, like Hippo, Hedgehog, and estrogen and androgen pathways, are involved. For example, GGPP increases membrane localization of Rho GTPases, which, in turn, activate YAP and TAZ, major downstream effectors of the Hippo pathway that controls cell proliferation, organ growth, and self-renewal of breast cancer stem cells (Sorrentino et al., 2014) . In addition, p53 loss has been known to activate Rho signaling and cell migration and invasion through downregulation of RhoE (Ongusaha et al., 2006) and upregulation of ROCK (Lefort et al., 2007) . In this context, derepressing the mevalonate pathway in p53 null tumors would provide more FPP and GGPP, which are critical for membrane localization and activity of Rho and would thus potentiate the Rho signaling. Which mevalonate pathway metabolites and which downstream pathways are dysregulated to contribute to tumorigenesis is likely to be contextdependent and will be the focus of future work.
HCC is a particularly difficult tumor with no effective therapies or druggable cancer drivers. When considering our observations, it is intriguing that human tumors with elevated expression of mevalonate pathway genes, like those with p53 mutations, are associated with poor prognosis (Clendening et al., 2010; Freed-Pastor et al., 2012) and that numerous studies indicate a beneficial effect of drugs that block the mevalonate pathway (i.e., statins) in reducing the risks of multiple cancers, including HCC (Mansourian et al., 2014; McGlynn et al., 2014; Shao et al., 2015; Singh et al., 2013) . Our study suggests therapeutic potential of targeting the mevalonate pathway for possible prevention of p53-deficient liver tumors. We also speculate that p53 status may become a prognostic and predictive marker for statin use in other types of cancers.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell culture SK-HEP-1 (human, male; previously obtained from American Type Culture Collection) and Hep3B (human, female; parental and 4Bv, a gift from M. Oren) cells were maintained in DMEM (Life Technologies) with 10% fetal bovine serum (FBS, Gemini Bio-products, catalog #900-108) and L-Glutamine:Penicillin:Streptomycin solution (Gemini Bio-products, catalog #400-110). HCT116 WT (p53+/+) and p53À/À cells (human, male) were a gift from B. Vogelstein (Johns Hopkins University) (Bunz et al., 1998) and maintained in McCoy's 5A medium (Life Technologies) with 10% FBS and L-Glutamine:Penicillin:Streptomycin solution. All cell cultures were maintained at 37 C in a humidified incubator with 5% CO 2 . For sterol starvation, cells were rinsed once with serum free medium and then placed in serum free medium or medium with 10% delipidated FBS (Gemini Bio-products, catalog #900-123, lot #A81D03E, A38D03D, A81D03E and Kalen Biomedical, catalog #880100-5, lot #BS017301, BS023201, BS025301).
Three-dimensional cultures
For RNA or protein analysis of 3D cultured HCT116 cells, 8-well chamber slides were lined with 50 ml growth factor-reduced Matrigel (Corning, catalog #356231, lot #28185 and #3072505). Cells were then seeded at a density of 5000 cells/well in the Assay Medium (DMEM/F12 + 2% Horse Serum + 10 mg/ml Insulin + 0.5 mg/ml Hydrocortisone + 5 ng/ml EGF) containing 2% Matrigel and refed every three days. Cells were harvested from Matrigel using Cell Recovery Solution (Corning, catalog #354253) according to the manufacturer's instructions.
Generation of SK-HEP-1 p53 null cells SK-HEP-1 p53 null cells were generated using CRISPR/Cas9 genome editing technology. SK-HEP-1 cells (human, male) were transfected with 1 mg of p53 CRISPR/Cas9 KO plasmid (Santa Cruz Biotech, catalog #sc-416469). To enrich for cells depleted of p53, cells were treated with Nutlin-3 (10 mM) for 6 days to inhibit proliferation of cells with WT p53 as previously described (Malina et al., 2013) . Single cell clones were selected via limiting dilution, and p53 null clones were confirmed by immunoblotting.
Animal studies
The Memorial Sloan Kettering Cancer Center (MSKCC) Animal Care and Use Committee (protocol no. 11-06-011) approved all mouse experiments. Mice were maintained under specific pathogen-free conditions, and food and water were provided ad libitum. For atorvastatin treatment trials, atorvastatin (prescription formulation; Pfizer Inc, New York, NY) was resuspended in PBS. Mice were given orally atorvastatin (100 mg/kg) or a similar volume of vehicle (PBS) three times per week. Mouse serum were collected in microtainer tube with serum separator (BD, catalog #365956).
Deriving tumor cell lines from murine liver tumors Tumors (from female mice) were dissected using sterile instruments, flushed with sterile phosphate-buffered saline (PBS), and cut into small pieces. Tumor tissues were then resuspended in 5-10 mL Dispase II/Collagenase D (Roche) solution in tubes and shaken for 30 min at 37 C. DMEM media containing 10% FBS and Penicillin:Streptomycin was added and the tubes were spun for 10 min at 1,300 rpm. Supernatants were discarded and cell pellets resuspended in DMEM media containing 10% FBS and Penicillin:Streptomycin and plated on Purecol (0.1 mg/ml, Advanced Biomatrix) coated dishes.
Hydrodynamic tail vein injection
A sterile 0.9% NaCl solution/plasmid mix was prepared containing pT3-EF1a-MYC (5 mg), pT3-EF1a-MYC-IRES-GFP (5 mg), CRISPR plasmid px330 DNA (Hsu et al., 2013 ) (20 mg) expressing Cas9 and single guide RNA (sgRNA) targeting either p53 or Axin1, Abca1, or Chr8 and pT3-EF1a-GFP-miRE transposon vector (20 mg) together with CMV-SB13 Transposase (1:5 ratio) for each injection. Female C57BL/6 mice (6-8 weeks of age) from Harlan Laboratories were randomly assigned to experimental groups to be injected with the 0.9% NaCl solution/plasmid mix into the lateral tail vein with a total volume corresponding to 10% of body weight in 5-7 s. The investigators were not blinded to the groups for the experiments. The pT3 transposon vector was a kind gift of Dr. Xin Chen, UCSF San Francisco. Complementary oligonucleotides used for cloning sgRNAs into pX330: Trp53 (Dow et al., 2015) 
Isolation of MYC-GFP positive primary hepatocytes
Hydrodynamic tail vein injection (HTVI) was performed on WT or p53 fl/fl ;Alb-Cre mice (both female from Bl6N background) using pT3-EF1a-MYC-IRES-GFP (5 mg) and CMV-SB13 Transposase (1 mg). Six days after injection, mice were anesthetized and their livers were perfused first with HBSS containing EGTA, then with HBSS containing Collagenase IV. Once digested, livers were gently dissociated, passed through a 100 mM cell strainer, and hepatocytes were concentrated by washing dissociated liver cells with low glucose DMEM, using low speed centriguation. Once hepatocytes were isolated, GFP positive hepatocytes were isolated by performing a low pressure sort, isolating only viable (DAPI negative) hepatocytes.
METHOD DETAILS
Reagents
The reagents used and working concentrations were as follows: Nutlin-3 (10 mM, Sigma-Aldrich, catalog #N6287), LG100268 (Sigma-Aldrich, catalog #SML0279), T0901317 (Sigma-Aldrich, catalog #T2320), 25-hydroxycholesterol (1 mg/ml, Santa Cruz Biotechnology, catalog #sc-214091), N-Acetyl-Leucyl-Leucyl-norleucinal (ALLN, 100 mM, Sigma-Aldrich, catalog #A6185), Simvastatin (10 mM, Sigma-Aldrich, catalog #S6196), mevalonic acid 5-phosphate (1 mM, Sigma-Aldrich, catalog #79849), geranylgeranyl pyrophosphate (10 mM, Sigma-Aldrich, catalog #G6025), GGTI-2133 (20 mM, Sigma-Aldrich, catalog #G5294), Palbociclib (500 nM, Selleck Chemicals, catalog #S1116) and Roscovitine (10 mM, Selleck Chemicals, catalog #S1153).
siRNA transfection
For RNAi, p53 siRNAs (Thermo Fisher Scientific, siRNA ID #s605 and #s606), ABCA1 siRNAs (Thermo Fisher Scientific, siRNA ID #s847 and QIAGEN, catalog #SI03115798 and #SI03025190) and HMGCR siRNA (Thermo Fisher Scientific, siRNA ID #s141) were used with Lipofectamine RNAiMAX (Thermo Fisher Scientific, catalog #13778-150). As negative controls, siRNA against Luciferase and Silencer Select Negative Control #1 siRNA (Thermo Fisher Scientific, catalog #4390843) were used.
Quantitative RT-PCR and microarray analysis Total RNA extraction and cDNA synthesis were carried out according to the manufacturer's instructions in the RNeasy Mini Kit (QIAGEN, catalog #74106) and QuantiTect Reverse Transcription Kit (QIAGEN, catalog #205313), respectively. Real-time PCR was carried out using either the Applied Biosystems StepOnePlus system using SYBR green dye (Thermo Fisher Scientific, catalog #4368708) or the Life Technologies ViiA 7 machine. Transcript levels were normalized to the levels of human RPL32 or mouse Rpl32 or Actb mRNA expression and calculated using the comparative C T method. Each qRT-PCR was done in triplicate using gene-specific primers. The list of qRT-PCR primers is included in Table S1 .
Quantitative chromatin immunoprecipitation
Chromatin Immunoprecipitation (ChIP) experiments were carried out as previously described (Freed-Pastor et al., 2012) . Cells were treated with 1% formaldehyde/PBS for 15 min at room temperature for crosslinking. Crosslinking was stopped by adding glycine to a final concentration of 125 mM and incubating for 5 min at room temperature. Cells were washed twice with cold PBS and lysed by incubating on ice for 30 min in RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% SDS, 50 mM Tris-HCl pH 8.0, 5 mM EDTA, and protease inhibitors). Lysed cells were sonicated to generate DNA fragments with an average length of about 500-1,000 bp. After sonication, samples were pelleted and supernatant was pre-cleared for 1 h with protein A/G beads pre-blocked with 1 mg/mL BSA and 0.3 mg/mL salmon sperm DNA. The pre-cleared chromatin was incubated with indicated antibodies and pre-blocked protein A/G beads. Antibodies used for ChIP were as follows: anti-SREBP-2 antibody (Abcam, catalog #ab30682), anti-p53 (DO-1) antibody, and mouse or rabbit IgG (Sigma-Aldrich, catalog #I5381 and #I5006) for a negative control. After overnight incubation at 4 C, beads were recovered by centrifugation and washed twice with RIPA buffer, four times with ChIP Wash Buffer (100 mM Tris-HCl pH 8.5, 500 mM LiCl, 1% NP-40, 1% deoxycholate), once again with RIPA buffer, and twice with TE buffer. The antibody/protein/ DNA complexes were eluted at 65 C for 15 min with 1% SDS and incubated with proteinase K (Thermo Fisher Scientific, catalog #AM2546), at 65 C overnight for reversal of formaldehyde crosslinking. DNA was purified using QIAquick PCR purification kit (QIAGEN, catalog #28106). ChIP-qPCR assay was performed using Power SYBR Green Master Mix (Thermo Fisher Scientific, catalog #4367659) and StepOnePlus Real-Time PCR system (Thermo Fisher Scientific). See Table S1 for primer sequences.
Immunoblotting
Cells were washed with cold PBS, pelleted, and resuspended in lysis buffer (50 mM HEPES-KOH at pH 7.9, 100 mM NaCl, 1.5 mM MgCl 2 , 1% NP-40, 5 mM ALLN and protease inhibitors (1 mM benzamidine, 3 mg/ml leupeptin, 0.1 mg/ml bacitracin, and 1 mg/ml macroglobulin)). The antibodies used for immunoblotting were anti-p53 (a mixture of in-house prepared DO-1 and 1801 hybridoma supernatants), anti-p21 (Santa Cruz Biotechnology, catalog #sc-397), anti-SREBP-2 (Thermo Fisher Scientific, catalog #PA1-338, for mouse SREBP-2), anti-ABCA1 (EMD Millipore, catalog #MAB10005 and Novus Biologicals, catalog #NB400-105) and anti-actin (Sigma-Aldrich, catalog #A2066). Anti-SREBP-2 (1D2, for human SREBP-2) antibody was purified from the hybridoma supernatant (ATCC, catalog #CRL2545).
Mouse tumor cell pellets were lysed in Laemmli buffer (100 mM Tris-HCl pH 6.8, 5% glycerol, 2% SDS, 5% 2-Mercaptoethanol). Equal amounts of protein were separated on 12% SDS-polyacrylamide gels and transferred to PVDF membranes. b-actin was monitored to ensure equal loading. Images were analyzed using the AlphaView software (ProteinSimple). Immunoblotting was performed using antibodies for MYC (1:1000, Abcam, catalog #ab32072), p53 (1:500, Leica Biosystems, catalog #NCL-p53-505), Axin1 (1:1000, Cell Signaling, catalog #2074), HMGCR (1:1000, Santa Cruz Biotechnology, catalog #sc-271595), LSS/OSC (1:500, Santa Cruz Biotechnology, catalog #sc-365129), b-actin (1:10000, Sigma-Aldrich, catalog #A1978).
Cell cycle analysis
For analysis of cell cycle changes during sterol starvation, cells were rinsed once with serum-free medium and then placed in medium with 10% delipidated FBS (Gemini Bio-products, catalog #900-123). Cells were harvested by trypsinzation at various time points and processed for flow cytometry. Cell pellets were washed twice with cold PBS and fixed with 50% ice cold ethanol. Cells were resuspended in PBS containing 62.5 mg/ml propidium iodide and 50 mg/ml RNase A. Propidium iodide-stained samples were analyzed on the Becton Dickinson FACSCalibur (BD Biosciences). The proportion of each cell cycle phase was quantitated using the ModFit LT Version 3.0 program (Verity Software House).
Analysis of the mevalonate pathway metabolites
Metabolomics analyses were performed on 20 ml of cell lysates (1x10 6 cells/mL of lysis buffer -methanol:acetonitrile:water 5:3:2 v/v) and pure methanol extraction (Optima, Thermo Fisher). Cells were resuspended in ice cold lysis buffers cells prior to vortexing for 30 min at 4 C and centrifugation for 10 min at 4 C and 12,000 g. Supernatants were diluted 1:1 (v/v) with 10 mM ammonium acetate for analysis by ultra-high pressure liquid chromatography coupled to mass spectrometry (UHPLC-MS) (D'Alessandro et al., 2014) .
Ultra-High Pressure Liquid Chromatography coupled to Mass Spectrometry
The analytical platform employs a Vanquish UHPLC system (Thermo Fisher Scientific, San Jose, CA, USA) coupled online to a Q Exactive mass spectrometer (Thermo Fisher Scientific, San Jose, CA, USA). Samples were resolved over an ACQUITY HSS T3 column (2.1 3 150 mm, 1.8 mm particle size (Waters, MA, USA) using an aqueous phase (A) of 25% acetonitrile and 5 mM ammonium acetate and a mobile phase (B) of 50% isopropanol, 45% acetonitrile and 5 mM ammonium acetate. Samples were eluted from the column using either the solvent gradient: 0-1 min 25% B and 0.3 mL/min; 1-2 min 25%-50% B and 0.3 mL/min, 2-8 min 50%-90% B and 0.3 mL/min, 8-10 min 90%-99% B and 0.3 mL/min, 10-14 min hold at 99% B and 0.3 mL/min, 14-14.1 min 99%-25% B 1and 0.3 mL/min, 14.1-16.9 min hold at 25% B and 0.4 mL/min, 16.9-17 min hold at 25% B and resume flow of 0.3 mL/min. isocratic elution of 5% B flowed at 250 ml/min and 25 C or a gradient from 0-5% B over 0.5 min; 5%-95% B over 0.6 min, hold at 95% B for 1.65 min; 95%-5% B over 0.25 min; hold at 5% B for 2 min, flowed at 450 ml/min and 35 C. The Q Exactive mass spectrometer (Thermo Fisher Scientific, San Jose, CA, USA) was operated independently in positive or negative ion mode, scanning in Full MS mode (2 mscans) from 150 to 1500 m/z at 70,000 resolution, with 4 kV spray voltage, 45 shealth gas, 15 auxiliary gas. When required, dd-MS2 was performed at 17,500 resolution, AGC target = 1e5, maximum IT = 50 ms, and stepped NCE of 25, 35 for positive mode, and 20, 24, and 28 for negative mode. Calibration was performed prior to analysis using the Pierce TM Positive and Negative Ion Calibration Solutions (Thermo Fisher Scientific). Acquired data was then converted from .raw to .mzXML file format using Mass Matrix (Cleveland, OH, USA). Samples were analyzed in randomized order with a technical mixture injected incrementally to qualify instrument performance. This technical mixture was also injected three times per polarity mode and analyzed with the parameters above, except CID fragmentation was included for unknown compound identification. Metabolite assignments, isotopologue distributions, and correction for expected natural abundances of deuterium, 13 C, and 15 N isotopes were performed using MAVEN (Princeton, NJ, USA) (Clasquin et al., 2012) , against an in house library of deuterated lipid standards (SPLASHâ LIPIDOMIXâ Mass Spec Standard, Avanti Lipids). Discovery mode analysis was performed with standard workflows using Compound Discoverer (Thermo Fisher Scientific, San Jose, CA).
Immunohistology
Tissue fixed in 10% neutral buffered formalin (NBF) for 24 hours, was embedded in paraffin and sectioned by IDEXX RADIL (Columbia, MO). Sections were deparafinized with Xylene and rehydrated with sequential washes of diluted ethanol (100%, 95%, 70%) followed by a dionized water wash. Antigens were unmasked with Vector Laboratories Unmasking Solution (catalog #H-3300) for 25 min in a pressure cooker set on high. Sections were treated with 3% H 2 O 2 for 10 min followed by a wash in dionized water (for IHC only), washed in PBS, then blocked in PBS/0.1% Triton X-100 containing 1% BSA. Primary chicken anti-GFP (1:500, #ab13970) antibody, mouse anti-ABCA1 antibody (1:200, #NB400-105), rabbit anti-c-Myc antibody (1:100, #ab39688), mouse anti-ABCA1 antibody (1:500, #ab18180), mouse anti-Ki67 (1:200, #BD550609), rabbit anti-CC3 (1:200, #9664), and mouse anti-OSC (1:200, #sc-365129) were incubated at 4 C overnight in blocking buffer. For IHC, chromogen development was performed using the secondary anti-chicken antibody (1:500, DyLight IgG, #ab96947), anti-rabbit ImmPRESS HRP-conjugated secondary antibodies (Vector Laboratories, #MP7401) and ImmPact DAB (Vector Laboratories, #SK4105). Stained slides were counterstained with Harris' hematoxylin. For immunofluorescence staining, sections were washed in PBS, followed by incubation with appropriate fluorescenceconjugated secondary antibodies for visualizing the immunosignals.
Immunohistology images were acquired on a Zeiss Axioscope Imager Z.1 using a 10 3 (Zeiss NA 0.3) or 20 3 (Zeiss NA 0.17) objective and an ORCA/ER CCD camera (Hamamatsu Photonics, Hamamatsu, Japan).
SURVEYOR assay
Cas9-induced mutations were detected using the SURVEYOR Mutation Detection Kit (Transgenomic/IDT). PCR primers for Surveyor assay: p53-SVR-F (CAGAAGATATCCTGGTAAGG), p53-SVR-R (CTACAGGCTGAAGAGGAACC) (Dow et al., 2015) ; Axin1-SVR-F (GCTTCCTGAAGCCACTGCAG), Axin1-SVR-R (CAGTAAGGAATGCAGTGACTC); Abca1 #1-SVR-F (TCAGCCACAATTCCCAC GAG), Abca1 #1-SVR-R (GGCAAGAACGGTGTGGAAGA), Abca1 #2-SVR-F (CCTTCCCATCATGCTCCACT), Abca1 #2-SVR-R (AAA TGGCTGTTGGCATACTGT), Abca1 #3-SVR-F (ACCAGTGAAAAACACGCACA), Abca1 #3-SVR-R (TGCTAGCCATACGTATTTTC ACAA).
RNA-seq of MYC-GFP positive primary hepatocytes RNA was isolated from GFP+, DAPI-sorted primary hepatocytes by use of Direct-zol RNA purification kit (ZYMO Research). RNA-Seq library construction was performed using standard Illumina TruSeq dual-indexing protocols and sequenced at CSHL in single-end 76 format on the Illumina HiSeq2500 instrument in Rapid mode for an average depth of 8 million reads per sample.
Figure preparation
Immunoblots for human p53, actin and p21 were derived by using IRDye fluorescent secondary antibodies (LI-COR) and were visualized using the Odyssey imaging system (LI-COR). Immunoblots for ABCA1 and SREBP-2 were prepared using Immobilion Enhanced Chemiluminescence (Millipore) and X-ray film.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis
Statistical significance between groups was calculated by two-tailed Student's t test unless otherwise specified. Statistical evaluation of tumor free survival in mouse experiments was based on the log-rank (Mantel-Cox) test for comparison of the Kaplan-Meier event-time format. Prism 6 and Microsoft Excel software were used to calculate the values. Power analysis was done using a two-group independent sample t test. Significance values are p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***) unless otherwise specified.
Expression analysis of Tet-Off shp53 liver tumor model Expression data measured by microarray following p53 reactivation in liver tumors was described in a previously published experiment (Tschaharganeh et al., 2014; Xue et al., 2007) and is deposited as NCBI GEO dataset GSE52091. Data was RMA normalized, log-transformed, and condensed by gene Entrez ID using the affy package (Gautier et al., 2004) implemented in R (http://cran. r-project.org/). Differential gene expression between Day 0 and Day 8 samples was determined by empirical Bayesian analysis within the LIMMA package (Smyth, 2004) . Complete dataset is available at NCBI Gene Expression Omnibus (GSE52091). The sex of the cell line used to produce tumors in this model is not known as the data was generated from embryos and is from a previously published dataset (Xue et al., 2007) .
Expression analysis of RNA-seq from MYC-GFP positive primary hepatocytes Expression data measured by RNA-seq is deposited as NCBI GEO dataset GSE121558. Raw sequencing data was analyzed by first removing adaptor sequences using Trimmomatic (Bolger et al., 2014) . These RNA-seq reads were then aligned to mouse GRCm38/ mm10 genome with STAR (Dobin et al., 2013) , and transcript count was quantified using featureCounts (Liao et al., 2014) to generate raw count matrix. Differential gene expression between p53 WT and p53 null hepatocytes was determined by running the DESeq2 package (Love et al., 2014) implemented in R (http://cran.r-project.org/).
Analysis of Cancer Cell Line Encyclopedia
Cancer cell lines from the Cancer Cell Line Encyclopedia (CCLE) (https://www.broadinstitute.org/ccle) were stratified based on p53 status: p53 null lines where defined as those with TP53 copy number less than log 2 ðÀ1Þ or harboring a nonsense or frameshift mutation, whereas p53 WT lines where defined as those with no homozygous copy number loss and no mutations. Microarray data from these cohorts were compared using the R package limma. Furthermore, to define a mevalonate gene expression signature value, each mevalonate pathway gene expression value was further converted to a z-score, and the mean of the 17 gene z-scores for each cell line was calculated.
Analysis of The Cancer Genome Atlas
The following datasets were downloaded from the Cancer Genome Atlas (TCGA) data portal -transcriptome expression (RNA-Seq V2), somatic mutations, clinical data, and copy number variations (segmented copy number calls) of the following tumor types: Liver Hepatocellular Carcinoma (LIHC), Colon Adenocarcinoma (COAD) and Breast Invasive Carcinoma (BRCA). All samples that included validated data for RNA-sequencing for mRNA expression and DNA sequencing for somatic mutation analysis were included in the analysis. When available, the matched normal samples pertaining to each tumor type was downloaded and used for the analysis. While considering somatic mutations, samples that had no reported mutations in a particular gene were assumed to be WT for that gene.
For purpose of the correlation analysis described in Table S5 , the liver tumor samples were stratified on the basis of their ABCA1 mutation status as WT and mutant. The samples with mutant ABCA1 were removed from the dataset. The tumor samples with no identified mutations in the ABCA1 gene are assumed to be WT. The transcriptome expression profiles were obtained from the RNA-seq V2 dataset. The Pearson correlation coefficient of the gene expression of the mevalonate pathway genes and the RNA expression of ABCA1 gene were calculated using MATLAB. The Pearson correlation and the associated p values were tabulated (Table S5 ).
For analysis of gene expression and plotting of box-plots showing differential gene expression across tumor and normal samples, the expression level of mRNA of particular genes was assessed and compared using the appropriate TCGA RNA-seq V2 datasets. For TCGA -Liver Hepatocellular Carcinoma (TCGA-LIHC) dataset, RNA-seq data pertaining to normal (n = 50) samples was compared versus tumor (n = 371) samples. Similarly, for TCGA-Colon Adenocarcinoma (TCGA-COAD), RNA-seq data of normal (n = 41) samples was compared versus tumor (n = 272) samples and for TCGA-Breast Invasive Carcinoma (TCGA-BRCA), RNAseq data of normal (n = 110) samples was compared versus tumors (n = 1037) samples.
In the case of comparing mRNA expression of specific genes in tumor samples with WT p53 versus samples with missense mutations in p53, the tumor samples were stratified on the basis of the p53 status. For the TCGA human liver cancer samples, tumors with WT p53 (n = 133) were compared to tumor samples with missense mutations (n = 40) in p53.
In the boxplots, the central line represents the sample median, and the notches display the variability of the median between samples (95% confidence interval). The width of a notch is calculated such that the box-plots whose notches do not overlap have different medians at the 5% significance level. Outliers are not displayed for clarity of the figure.
In these cases, statistical significance was determined by p-values as computed by Welch's two-tailed t test (assuming unequal variances). When appropriate, the statistical tests were corrected for multiple testing as needed by False Discovery Rate (FDR correction) as determined by the Benjamini-Hochberg procedure. Most analysis was performed and box-plots for the figures were plotted using MATLAB.
Gene ontology and Gene set enrichment analysis analyses GO analysis was performed using DAVID Bioinformatics Resources. Genes that are significantly associated with p53 restoration (by Gene Ontology) are included in Table S2 . Gene set enrichment analysis (Subramanian et al., 2005) was performed using GSEA v2.07 software. Gene sets used in this study are included in Table S3 . A detailed description of GSEA methodology and interpretation is provided at https://www.broadinstitute.org/gsea/doc/GSEAUserGuideFrame.html. Significance of gene sets from the GSEA was based on the normalized enrichment score (NES) and the false discovery rate q-value (FDR q-val) to determine the probability that a gene set with a given NES represents a false-positive finding.
DATA AND SOFTWARE AVAILABILITY
Primary hepatocyte expression data is available on the NCBI Gene Expression Omnibus (GEO) database under accession number GEO: GSE121558. ACAT2  HMGCS1  HMGCR  MVK  MVD  IDI1  FDPS  FDFT1  SQLE  LSS  CYP51A1  SC4MOL  NSDHL  DHCR7  DHCR24  ACAT2  HMGCS1  HMGCR  MVK  MVD  IDI1  FDPS  FDFT1  SQLE  LSS  CYP51A1  SC4MOL  NSDHL  DHCR7 Figure 1C was re-plotted to reveal the baseline levels in the HCT116 p53À/À cells. The mRNA expression levels in DMSO-treated WT cells were set to 1.
(B) Hep3B-4Bv cells harboring the temperature-sensitive A135V mutant p53 and the parental Hep3B p53 null cells were cultured for 72 hours at 37 C or 32 C. Expression of the mevalonate pathway genes HMGCR and FDFT1 was assessed by qRT-PCR (n = 3, * denotes p < 0.01). Error bars represent SDs of the means. p21 mRNA expression was assessed as a positive control for WT p53 transcriptional activity. mRNA expression levels at 37 C were set to 1. (C) Scheme for producing murine liver carcinomas with re-activatable p53. Liver progenitor cells (LPCs) were infected with retroviruses expressing oncogenic H-rasV12 coupled with GFP, tetracycline transactivator (tTA) and a doxycycline repressible shRNA targeting p53. Transformed LPCs were then introduced into the livers of retrorsine-pretreated female NCR nu/nu mice (6-8 weeks of age) by intra-splenic injection. After tumor onset mice were fed with doxycycline containing water (Xue et al., 2007) . Eight days later tumors were harvested and RNA was extracted using Trizol. (D) Genome-wide analysis of differential expression of murine liver carcinomas following reconstitution of p53 with respect to tumors with sustained p53 knockdown. Volcano plot depicts the significance (false discovery rateadjusted p-value) and magnitude of difference (fold change Figure 2D . HCT116 WT (p53+/+) and p53À/À cells were cultured for 24 hours as in Figure 2D in FBS (1), DL-FBS (2) or DL-FBS+25-HC (3). The proteasome inhibitor ALLN was added 3 hours prior to harvest. (C) Related to Figure 2C . HCT116 cells were cultured for 24 hours in sterol-depleted medium and subjected to chromatin immunoprecipitation (ChIP) analysis to examine p53 occupancy at the promoters of the indicated mevalonate pathway genes. p53 binding to the p21 5 0 distal binding site (p21 5 0 RE) was performed as a positive control. HMGCR (TSS À150), HMGCS1 (TSS À115) and FDPS (TSS À260) correspond to their respective sterol regulatory elements (SREs). Error bars represent SDs of the means. Figure S4 . ABCA1 Is Transactivated by p53 and Inhibits SREBP-2 Maturation, Related to Figure 4 (A) Related to Figure 4E . HCT116 cells were treated with Nutlin-3 and subjected to chromatin immunoprecipitation analysis with IgG (white bars) or anti-p53 antibody (black bars) to examine p53 occupancy at the ABCA1 promoter (n = 2). Putative p53 response elements are found at $110 and $1690 bp downstream regions of the transcriptional start site (TSS). Error bars represent SDs of the means. (B) H24 cells are a variant of H1299 p53 null cells in which WT p53 or transactivation domain mutant p53 (L22Q/W23S) are induced upon withdrawal of tetracycline (''tet-off'') (Chen et al., 1996) . ABCA1 mRNA and protein expression before and after induction were assessed (n = 2). Error bars represent SDs of the means. (C) SK-HEP-1 p53 null cells were transfected with negative control siRNA or ABCA1 siRNAs and sterol-starved for 8 hours in the presence of the LXR agonist T0901317 (20 nM). (D) Mouse embryonic liver progenitor cells were transduced in vitro with retroviruses expressing H-rasV12, tet-off p53 shRNA and tTA. The cells were cultured in the presence of doxycycline to restore p53 expression and harvested at Days 0, 4 and 8. Expression of p53, Cdkn1a, Abca1 was assessed by qRT-PCR (n = 3). The mRNA expression levels were normalized to Day 0 samples. Error bars represent SDs of the means. (E) Related to Figure 4I . Expression of CDKN1A and BBC3 mRNA in liver tumors with WT p53 (n = 133) and missense mutations (n = 40) was compared (p < 0.0467 and p < 0.0206, respectively). (F) Related to Figure 4J . High ABCA1-and low ABCA1-expressing cancer cells were defined with a cutoff z = 0.5 (dashed line). (G-I) Asynchronized SK-HEP-1 parental (WT p53) and p53 null cells (G) were synchronized by either double thymidine block (H) or Palbociclib treatment (I) (500 nM for 24 hours). Cell cycle distribution was analyzed and a representative flow cytometric graph was shown. ABCA1 mRNA levels were assessed by qRT-PCR (n = 2$3). The expression levels in the parental cells were set to 1. Error bars represent SDs of the means. Hmgcr mRNA expression shRen shHmgcr Figure S6 . RNAi or Pharmacological Inhibition of Mevalonate Pathway Genes In Vivo Restricts p53-Mutated HCC Development, Related to Figure 6 (A) The expression profile upon p53 restoration in murine liver carcinomas harboring oncogenic ras (H-rasV12) (Xue et al., 2007) was cross-analyzed with the published result from an RNAi screen that systematically probed candidate drug targets required for murine MYC;p53À/À HCC maintenance (Huang et al., 2014) (Table S4 ). (B) Murine MYC;p53À/À HCC cells were transduced with TRMPV-Neo-miR-E constructs expressing doxycycline-inducible shRNA against Renilla luciferase, Hmgcr, Sqle or Lss as previously described (Huang et al., 2014) . The cells were cultured in the presence of doxycycline for shRNA induction and harvested at Day 3. RNA from these transduced HCC cells was obtained and expression of mevalonate pathway genes was assessed by qRT-PCR (n = 3) to confirm the knockdown efficiency of the shRNA constructs. The mRNA expression levels were normalized to shRenilla samples. MYC stained for Ki67 and Cleaved Caspase 3 (CC3). (D) Quantification of stained tumors. Five 20x fields from independent tumors were quantified. To avoid necrotic regions, images and quantification were taken at tumor periphery. Values were expressed as % on total tumor cell number. All comparisons were nonsignificant except for Ki67 quantification of sgp53 and sgAbca1.1 which was marginally significant with p = 0.0214. Quantification was done blind and p-values were obtained by unpaired t test method.
